GEN Exclusives

More »

GEN News Highlights

More »
Apr 12, 2011

Daiichi Will Pay Pieris About $10.2M to Leverage Its Anticalin Technology

  • Pieris and Daiichi Sankyo signed a a collaboration and license agreement under which Pieris will use its Anticalin scaffold technology against two targets to be provided by Daiichi Sankyo. Pieris will receive more than €7 million ($10.2 million) upon signing of the collaboration agreement for the two targets.

    The partnership could generate for Pieris more than €100 million (approximately $145.1 million) per target in license fees, funding, and milestones provided the nominated Anticalin achieves full commercialization. Pieris is also entitled to tiered, mid- to mid-high single-digit royalties.

    Upon discovery and achievement by Pieris of early preclinical development milestones for lead candidates, Daiichi Sankyo will assume responsibility for further development of the Anticalin compounds. Daiichi Sankyo will have exclusive marketing rights worldwide for all products to be produced through the agreement.

    Anticalins are recombinantly engineered lipocalins, endogenous low-molecular weight human proteins that naturally bind, store, and transport a wide spectrum of molecules. Lipocalins' diversity has yielded a class of drugs that provides specificity and affinity against a wide spectrum of targets, exhibits the safety of an endogenous protein performing an endogenous function, and is durable, creating greater flexibility of formulation and delivery, Pieris explains. Through rational diversification of the lipocalin regions that are responsible for ligand binding, the company has created phage display libraries.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »